U.S. Equity Strategy: Round Trip Back To Resistance
Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...
216 Views
U.S. Equities: Test Of The Lows Coming?
Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential...
352 Views
Adaptive Biotechnologies IPO: Immune to Grow and Succeed; and the Future Looks Good
Adaptive Biotechnologies (ADPT US) has filed for an IPO in the US to raise approximately US$181m and has set an IPO price range of US$15-17 per...
352 Views
No more insights